임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
24건 표시
- 2상모집 중단 (진행 중)· Depressive Disorder, MajorA Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· X-Linked Retinitis PigmentosaA Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Alzheimer DiseaseA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· High-Risk de Novo Multiple MyelomaTeclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungPremedication to Reduce Amivantamab Associated Infusion Related Reactions
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Colitis, UlcerativeA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Crohn's DiseaseA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· MyositisA Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· AmyloidosisA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Aggressive Variant Prostate CarcinomaCabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Urinary Bladder NeoplasmsA Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Prostatic NeoplasmsAdjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Hematological MalignanciesA Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaDaratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
협력: 암젠, 얀센(J&J)
- 2상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
리드: 애브비 · 협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Prostatic Neoplasms, Castration-ResistantA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Urothelial CancerAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
리드: 얀센(J&J)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.